Werkgroep Cardiologische centra Nederland English

RELAX-AHF-II (Klaar)

A multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patientsA multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients

Middel
RLX030 serelaxine
Populatie
hartfalen
Fase
III
Jaar aanvang
2013
Meer informatie
ClinicalTrials.gov

Studiedirecteur

drs. H.P. Swart (Cardioloog)
Sneek, D&A Research and Genetics

RELAX-AHF-II: Nieuws